Vincristine, Irinotecan, and Bevacizumab in Relapsed Wilms Tumor with Diffuse Anaplasia

Not yet translated Not yet translated
Category Primary study
JournalJournal of Pediatric Hematology/Oncology
Year 2018
The prognosis of relapsed Wilms tumor (WT) with diffuse anaplasia is dismal, therefore, novel therapeutic strategies need to be explored. We reported on 2 consecutive cases with relapsed anaplastic WT who presented a partial response after 2 courses of vincristine, irinotecan, and bevacizumab association. This regimen may have a role in the treatment of patients with anaplastic advanced WT.
Epistemonikos ID: ee1d2fc34e69b72e7fa1264be2ec0731601df119
First added on: Jun 14, 2024